Fig. 2From: Efficacy and safety of different Janus kinase inhibitors combined with methotrexate for the treatment of rheumatoid arthritis: a single-center randomized trialComparison of the rates of disease activity score in 28 joints, C-reactive protein (DAS28-CRP) remission (a) and DAS28-CRP-low disease activity (LDA) achievement (b) between the two groups after 1 month and 6 months of treatment. Numbers represent the percentages of all patients (%)Back to article page